"The Federal Circuit's decision in Teva Pharmaceuticals International GmbH v. Eli Lilly & Co. clarifies that method claims for using known compounds are subject to different evaluation standards under 35 U.S.C. § 112, particularly in the context of the Amgen decision."
"The court's unanimous ruling reversed a district court's judgment that had overturned a jury's finding of willful infringement, reinstating a significant $177 million damages award for Teva."
"This case serves as a critical test of the boundaries of the post-Amgen disclosure doctrine, particularly as it pertains to method-of-treatment claims versus composition claims."
The Supreme Court's 2023 decision in Amgen Inc. v. Sanofi heightened disclosure demands for genus claims in pharmaceuticals. The Federal Circuit's application in Baxalta Inc. v. Genentech raised concerns about the viability of broad antibody claims. In Teva Pharmaceuticals International GmbH v. Eli Lilly & Co., the court established that method claims for known compounds are evaluated differently under 35 U.S.C. § 112. The ruling reinstated a jury's verdict of willful infringement and $177 million in damages for Teva's Ajovy against Lilly's Emgality, emphasizing the importance of the method-of-treatment claim distinction.
Read at Patently-O
Unable to calculate read time
Collection
[
|
...
]